By Rory McCann, Marketing Manager & Conference Producer, LSN
Eran is very active in the world of early-stage startups and fundraising within life science and is a recent contributor to the Redefining Early Stage Investments (RESI) community. Eran speaks with us about the value he’s found at RESI and how his many roles helped him make the most of his experience and add value to others.
Digital RESI takes place June 8-10. There’s still time to save on early bird rates, sign up by May 7 to save!
By Rory McCann, Marketing Manager & Conference Producer, LSN
APIE Therapeutics is an early-stage company developing vascular endothelium niche repair and regeneration. We spoke with CEO, Dr. Esther Alegría about the early days of APIE Therapeutics and the importance of fit when seeking capital and building a powerful team.
APIE Therapeutics is an Innovator’s Pitch Challenge winner at last month’s Longevity, Health & Innovation, a Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by May 7 to save $50 on early bird rates.
RESI Longevity, September 16-17, is now accepting Innovator’s Pitch Challenge applications. Learn more and sign up by July 23 to save!
By Rory McCann, Marketing Manager & Conference Producer, LSN
Panaceutics Rx is an early-stage company advancing accessible personalized medicine based on patients’ digital health profiles using robotic platforms and patented processes.
We spoke with Panaceutics CEO, Edison Hudson about the need for more accessible adherence to life-saving therapies and Panaceutics’ approach to working with hospitals, investors, and physicians.
Panaceutics Rx is an Innovator’s Pitch Challenge winner at last month’s Longevity, Health & Innovation, a Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by May 7 to save $50 on early bird rates.
By Rory McCann, Marketing Manager & Conference Producer, LSN
Creative Bio-Peptides is an early-stage company, founded and led by Dr. Michael Ruff, with a mission to improve lives through developing oral receptor-active peptides targeting neurodegenerative diseases. We spoke with Chief Business Officer, Michael Simon about the early-stage journey of Creative Bio-Peptides – how it was started, what their strategy looks like today, and where they see the company going forward.
Creative Bio-Peptides is a past participant at an Redefining Early Stage Investments (RESI) partnering event. Learn more about RESI and sign up by April 9 to save $100 on super early bird rates.
By Rory McCann, Marketing Manager & Conference Producer, LSN
When fundraising executives seek out a successful partnering experience, so many define success with deals and checks. At Life Science Nation, we frequently hear success stories that do end with capital and funding, but many do not. Instead, these stories touch on the benefits of successful partnering that impact company growth and bottom line in other ways, often the details that are taken for granted when seeking strategic partners.
Neuro20 Technologies is one such success story. They attended their first digital RESI conference looking for capital but came out with so much more. Listen to their story, and sign up for Digital RESI JPM to learn more from the Neuro20 Technologies team and start your partnering success story!
By Rory McCann, Marketing Manager & Conference Producer, LSN
The Inaugural Longevity, Health & Innovation digital partnering event launches next week! This conference, co-organized by Life Science Nation (LSN) and Mary Furlong & Associates (MFA), is designed to bring early-stage companies and investors together, along with industry leaders, to advance deals in the longevity marketplace in order that seniors live longer, healthier lives.
I spoke with LSN CEO, Dennis Ford and MFA CEO, Dr. Mary Furlong on their partnership and thoughts on the industry, particularly where Longevity, Health & Innovation fills the gap in the early-stage ecosystem. There is still time to sign up and begin meeting with leaders in the field – Learn more at https://longevityhealthinnovation.com/.
By Rory McCann, Marketing Manager & Conference Producer, LSN
Helena Cowley, MS, MBA is CEO of Oxidien Pharmaceuticals, a therapeutics company mitigating kidney stone disease by using enzyme compounds to treat secondary hyperoxaluria. We recorded our chat about the early days of Oxidien and how they’ve navigated the fundraising landscape. We discuss conferences, networking, and tools to give early-stage companies an edge when meeting with strategic partners.
To learn more about RESI and Life Science Nation’s premier partnering events this September, visit www.resipartneringweek.com. Digital RESI Partnering Week September super early bird rates apply until July 23, so sign up today to start meeting with investors and strategic partners to jumpstart your 2021 fundraising goals!
Next Phase Newsletter 